PolyPeptide Group AG
PPGN.SW
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.45B
Close$
$-17.98
140.6% downside
Current Fair Value
140.6% downsideOvervalued by 140.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.45 Billion |
|---|---|
| Enterprise Value | $1.61 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.64 |
| Beta | 1 |
| Outstanding Shares | 33,016,410 |
Return
| Return on Equity | -5.75% |
|---|---|
| Return on Assets | -2.35% |
| Return on Invested Capital | 3.83% |
Valuation & Multiples
| P/E Ratio | 109.59 |
|---|---|
| PEG | -81.69 |
| Price to Sales | 1.77 |
| Price to Book Ratio | 4.43 |
| Enterprise Value to Revenue | 1.95 |
| Enterprise Value to EBIT | 64.68 |
| Enterprise Value to Net Income | -80 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.62 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$201.25 M
Average shareholder expectationNext Earnings Call
Expected Date
March 9, 2027
EPS Estimate
$0.47
Average shareholder expectationRevenue Estimate
$244.94 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About PolyPeptide Group AG
1,469 employees
CEO: Juan Jose Gonzalez Operating globally, PolyPeptide Group AG functions as a prominent contract development and manufacturing organization (CDMO). The company specializes in producing both proprietary and generic GMP-certified peptides, which are supplied to...